Candidate Compounds Covid19
| Zeile 6: | Zeile 6: | ||
*[[reviews on covid drug development]] ''with content'' | *[[reviews on covid drug development]] ''with content'' | ||
| − | * | + | *[[scouting ideas]] |
*[[Patients on biologicals]] | *[[Patients on biologicals]] | ||
| Zeile 19: | Zeile 19: | ||
*[[post-Interleukin 1]] | *[[post-Interleukin 1]] | ||
*[[Inflammasome]] | *[[Inflammasome]] | ||
| − | + | *[[other anti-innflammatory]] | |
*[[NK-kappaB]] | *[[NK-kappaB]] | ||
*[[STAT 3]] | *[[STAT 3]] | ||
| Zeile 64: | Zeile 64: | ||
*[[Traditional Chinese Medicine]] | *[[Traditional Chinese Medicine]] | ||
*[[Natural compounds]] | *[[Natural compounds]] | ||
| + | |||
| + | *[[Antidiabetic compounds, any]] | ||
| + | *[[RSP - On RAS drugs]] | ||
*[[Reconvalescent blood products, Passive vaccine]] ''with content'' | *[[Reconvalescent blood products, Passive vaccine]] ''with content'' | ||
| Zeile 69: | Zeile 72: | ||
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations | *[[Immunodeviation]] e.g. by adjuvants or other vaccinations | ||
| + | *[[Radiation therapy]] | ||
*[[Active vaccine]] ''with cotent'' | *[[Active vaccine]] ''with cotent'' | ||
| − | + | ||
| Zeile 154: | Zeile 158: | ||
| − | + | ||
{{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}} | {{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}} | ||
| Zeile 161: | Zeile 165: | ||
| − | + | ||
| Zeile 177: | Zeile 181: | ||
| − | + | ||
{{tp|p=32318324|t=ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |pdf=|usr=}} | {{tp|p=32318324|t=ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |pdf=|usr=}} | ||
| Zeile 202: | Zeile 206: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
{{tp|p=32271462|t=2020. Inositol and pulmonary function Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}} | {{tp|p=32271462|t=2020. Inositol and pulmonary function Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}} | ||
| Zeile 231: | Zeile 235: | ||
| − | + | ||
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}} | {{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}} | ||
{{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}} | {{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}} | ||
| Zeile 239: | Zeile 243: | ||
| − | + | ||
| Zeile 248: | Zeile 252: | ||
{{tp|p=32251365|t=ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy |pdf=|usr=}} | {{tp|p=32251365|t=ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy |pdf=|usr=}} | ||
| − | + | ||
| Zeile 262: | Zeile 266: | ||
| − | |||
| − | |||
| Zeile 271: | Zeile 273: | ||
| − | |||
| − | + | ||
| + | |||
| + | |||
| + | |||
| Zeile 299: | Zeile 303: | ||
| − | + | ||
{{tp|p=32305009|t=ä. Investigating hypothiocyanite against SARS-CoV-2 |pdf=|usr=}} | {{tp|p=32305009|t=ä. Investigating hypothiocyanite against SARS-CoV-2 |pdf=|usr=}} | ||
| Zeile 307: | Zeile 311: | ||
| − | |||
| Zeile 313: | Zeile 316: | ||
| − | + | ||
| + | |||
| Zeile 320: | Zeile 324: | ||
| − | |||
| Zeile 332: | Zeile 335: | ||
| − | + | ||
| + | |||
{{tp|p=32326426|t=2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |pdf=|usr=}} | {{tp|p=32326426|t=2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |pdf=|usr=}} | ||
| Zeile 340: | Zeile 344: | ||
| − | |||
| − | + | ||
| + | |||
{{tp|p=32373322|t=ä. Fighting COVID-19 with water |pdf=|usr=}}''dehydration of mucous glycans'' | {{tp|p=32373322|t=ä. Fighting COVID-19 with water |pdf=|usr=}}''dehydration of mucous glycans'' | ||
| Zeile 351: | Zeile 355: | ||
| − | |||
| − | + | ||
| + | |||
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}} | {{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}} | ||
| − | |||
| Zeile 369: | Zeile 372: | ||
| − | + | ||
| + | |||
{{tp|p=32324533|t=2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients |pdf=|usr=}} | {{tp|p=32324533|t=2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients |pdf=|usr=}} | ||
| Zeile 382: | Zeile 386: | ||
| − | |||
| − | |||
| Zeile 390: | Zeile 392: | ||
| − | |||
| − | + | ||
| − | + | ||
| − | + | ||
| + | |||
| + | |||
| + | |||
{{tp|p=32339473|t=ä. Probiotics and COVID-19: one size does not fit all |pdf=|usr=}} | {{tp|p=32339473|t=ä. Probiotics and COVID-19: one size does not fit all |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 411: | Zeile 409: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 424: | Zeile 417: | ||
| − | + | ||
| − | + | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
*''riociguat?'' | *''riociguat?'' | ||
| − | + | ||
| Zeile 443: | Zeile 447: | ||
| − | + | ||
{{tp|p=32335456|t=2020. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?|pdf=|usr=}} | {{tp|p=32335456|t=2020. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?|pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32353355|t=ä. Testosterone, a key hormone in the context of COVID-19 pandemic |pdf=|usr=}} | {{tp|p=32353355|t=ä. Testosterone, a key hormone in the context of COVID-19 pandemic |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32255312|t=2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2 |pdf=|usr=}} | {{tp|p=32255312|t=2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2 |pdf=|usr=}} | ||
{{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}} | {{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 479: | Zeile 472: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32340216|t=2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections |pdf=|usr=}} | {{tp|p=32340216|t=2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections |pdf=|usr=}} | ||
{{tp|p=32342019|t=ä. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity) |pdf=|usr=}} | {{tp|p=32342019|t=ä. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity) |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ||
| + | |||
{{tp|p=32307559|t=ä. Management for patients with pediatric surgical disease during the COVID-19 epidemic |pdf=|usr=}} | {{tp|p=32307559|t=ä. Management for patients with pediatric surgical disease during the COVID-19 epidemic |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 509: | Zeile 490: | ||
| − | |||
| − | |||
| − | + | ||
| − | + | ||
| + | |||
{{tp|p=32342871|t=ä. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?|pdf=|usr=}} | {{tp|p=32342871|t=ä. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?|pdf=|usr=}} | ||
| Zeile 523: | Zeile 503: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 560: | Zeile 536: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32297156|t=ä. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2 |pdf=|usr=}} | {{tp|p=32297156|t=ä. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2 |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ||
| Zeile 610: | Zeile 568: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ||
| + | |||
{{tp|p=32229155|t=2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?|pdf=|usr=}} | {{tp|p=32229155|t=2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?|pdf=|usr=}} | ||
| Zeile 644: | Zeile 587: | ||
{{tp|p=32362106|t=2020. Management of conjunctivitis during the COVID-19 pandemic 2020 |pdf=|usr=}} | {{tp|p=32362106|t=2020. Management of conjunctivitis during the COVID-19 pandemic 2020 |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
Version vom 21. Juni 2020, 11:27 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
current items will be put into the subsections. subsections with contents are marked with content. the others are pending data.
- reviews on covid drug development with content
- scouting ideas
- Patients on biologicals
- HMGB1, RAGE
- pre-Interleukin 6 with content
- post-Interleukin 6
- pre-TNFalpha
- post-TNFalpha
- pre-Interleukin 17
- post-Interleukin 17
- pre-Interleukin 1
- post-Interleukin 1
- Inflammasome
- other anti-innflammatory
- NK-kappaB
- STAT 3
- JAK Janus Kinase
- Corticosteroids
- Cytokine absorbers
- Target Complement system
- Target Extracellular traps
- Anticoagulant in covid19
- Antioxidants
- Stem cells
- MDSC cells
- Immunodeviation e.g. by adjuvants or other vaccinations
- Radiation therapy
- Active vaccine with cotent
Microbiome as target
32356654 ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles
stem cells
32257554 2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
32257537 2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
32283815 2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use
32241793 2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
CRISPR genome editing technology
32353252 ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Virus interference
32071427 2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses
resilience enhancement
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32311498 ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
psychoneuroimmunology
32234338 ä. Using psychoneuroimmunity against COVID-19
Exercise
32311497 ä. The immunological case for staying active during the COVID-19 pandemic
Topical agents opening up the world of nano...
32222466 2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
32305181 ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection
32360083 ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients
32277367 ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
32373721 2020. Low dose lung radiotherapy for COVID-19 pneumonia The rationale for a cost-effective anti-inflammatory treatment
32318324 ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival
32360420 ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia
32335366 2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis
32333972 ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4 inhibition play a role??
32333966 2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications
32333969 ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too
32283128 ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? on ace2 via adam17, nfkb via dpp4
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32271462 2020. Inositol and pulmonary function Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32117569 2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China
32247692 ä. Faecal-oral transmission of SARS-COV-2: practical implications
32367287 ä. New evidence of SARS-CoV-2 transmission through the ocular surface
32251365 ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy
32366728 2020. Medical Education During the COVID-19 Pandemic: A Single Institution Experience
32366726 2020. Management of Asthma in Children during COVID-19 Pandemic
32366725 2020. COVID -19 Pandemic: The Challenges for Pediatric Oncology
32283177 ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections
32226290 2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19
32305009 ä. Investigating hypothiocyanite against SARS-CoV-2
32354030 2020. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32326426 2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression
32373322 ä. Fighting COVID-19 with water dehydration of mucous glycans
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32324533 2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients
32291198 2020. Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management
32339473 ä. Probiotics and COVID-19: one size does not fit all
- riociguat?
32344313 ä. Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?
32344312 2020. Potential effect of natural and anabolizan steroids in elderly patient with COVID-19
32344310 2020. Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality
32335456 2020. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
32353355 ä. Testosterone, a key hormone in the context of COVID-19 pandemic
32255312 2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2
32365556 2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease
32340216 2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections
32342019 ä. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity)
32307559 ä. Management for patients with pediatric surgical disease during the COVID-19 epidemic
32342871 ä. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?
32342874 ä. Low dose radiation therapy for COVID-19 pneumonia: a double-edged sword
32297156 ä. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2
32191676 2020. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?
32229155 2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?
32282033 2020. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic
32362106 2020. Management of conjunctivitis during the COVID-19 pandemic 2020
32315229 2020. COVID-19 and the CRISPR Community Response
32133962 2020. Effective Chemicals against Novel Coronavirus (COVID-19) in China
32227357 ä. COVID?19 treatment by repurposing drugs until the vaccine is in sight
32377559 ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
32374010 2020. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?
32374009 2020. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19
32369103 ä. Sacubitril/valsartan in COVID-19 patients: the need for trials
32373994 2020. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope
32373992 2020. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment
32362193 2020. Quadruple therapy for asymptomatic COVID-19 infection patients
32366131 2020. Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine
32336007 2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?
32224164 2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?
32281695 2020. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases
32379896 2020. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs
32157732 ä. Harnessing the immune system via Fc?R function in immune therapy: a pathway to next?gen mAbs
32298218 2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
32317431 2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
32370727 2020. SARS-CoV-2 & Covid-19: Key-Roles of the Renin-Angiotensin System / Vitamin D Impacting Drug and Vaccine Developments
| 32377694 2020. Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review) |
32338559 2020. Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?
32310190 2020. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
32306822 2020. Peptide-like and small-molecule inhibitors against Covid-19
32364041 2020. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2
üüp
32349031 2020. Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection
32379348 2020. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics
32219882 ä. Controversial treatments: An updated understanding of the coronavirus disease 2019
32108352 ä. Clinical trial analysis of 2019?nCoV therapy registered in China
32356910 2020. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review
32239514 ä. Comments on Zhang et al: Clinical trial analysis of 2019?nCoV therapy registered in China
| 32378064 ä. Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms |
32320059 2020. Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism
32297985 2020. Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China
32293713 2020. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China
32285942 2020. Defining Protective Epitopes for COVID-19 Vaccination Models
32281679 2020. COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy
32380023 ä. Immunomodulation in COVID-19
32367857 2020. Safety of an immunomodulator Mycobacterium w in COVID-19
32367847 2020. Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID-19?
32371362 2020. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
32366816 2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
32376359 ä. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
32219429 2020. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges
32352484 2020. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19
32208486 2020. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics
32297900 2020. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis
32282022 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32372435 2020. Drug repurposing in the era of COVID-19: a call for leadership and government investment
32324177 2020. Some drugs for COVID-19
32375002 ä. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery
| 32378459 2020. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses |
| 32363750 2020. A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL) |
32227757 2020. Developing Covid-19 Vaccines at Pandemic Speed
32289216 2020. Drug Evaluation during the Covid-19 Pandemic
32273591 2020. The COVID-19 vaccine development landscape
32269311 2020. Coordinating the COVID-19 pipeline
32127666 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
32355243 2020. Scores of coronavirus vaccines are in competition - how will scientists choose the best?
32353859 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
32300225 2020. On the front lines of the coronavirus-vaccine battle
32346146 2020. The race for coronavirus vaccines: a graphical guide
32377399 2020. COVID-19 vaccines: breaking record times to first-in-human trials
32297843 2020. Oligonucleotides and the COVID-19 Pandemic: A Perspective
32275178 2020. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease
32216577 2020. Artificial intelligence and machine learning to fight COVID-19
32352615 2020. Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2
32259313 2020. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
32295694 2020. COVID-19 vaccination clinical trials should consider multiple doses of BCG
32326830 2020. Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management
32330404 2020. Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?
32374874 ä. COVID-19: an unexpected indication for anti-rheumatic therapies?
32376603 ä. Development of an inactivated vaccine candidate for SARS-CoV-2
32301312 2020. Vaccins anti-covid-19 : les recherches de johnson & johnson, sanofi et pasteur
32355008 2020. COVID-19 shot protects monkeys
32292113 2020. Stem Cell?Based Therapy for Coronavirus Disease 2019
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
32302280 2020. Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
32220178 2020. Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019
32374891 2020. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design
32374890 2020. COVID-19 convalescent plasma: phase 2
32245869 2020. Possible treatment of Covid-19 with a therapeutic vaccine
32221001 2020. Possible method for the production of a Covid-19 vaccine
32324899 2020. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy
32319102 2020. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma
32240545 2020. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?
| 32281329 2020. Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway |
32164080 2020. Potential antiviral therapeutics for 2019 Novel Coronavirus
32164081 2020. Pharmacotherapeutics for the new coronavirus pneumonia
32164077 2020. Pharmacotherapeutic about the new coronavirus pneumonia
32234130 2020. Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)
C7180667 ä. Achilles heel of the killer virus: the highly important molecular targets for hitting SARS-CoV-2 that causes COVID-19
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
C7152890 2020. Biomimetic nanoparticles as universal influenza vaccine
C7187737 ä. COVID-19 and the Rationale for Pharmacotherapy: A South African Perspective
C7167691 2020. (Deutsche Szene) Schutz vor und Hilfe bei Covid19 Infektionen
C7189010 2020. Biologika und Covid-19
32387535 ä. Asthma, biologics, corticosteroids, and coronavirus disease 2019
C7197606 ä. Antibody therapies for the treatment of COVID-19
32380316 2020. Convalescent plasma in Covid-19: Possible mechanisms of action
32376392 2020. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
32389697 ä. Plasmapheresis treatment in COVID-19?related autoimmune meningoencephalitis: Case series
32437659 2020. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection
| 32402856 2020. Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2? |
C7151553 2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
28945945 2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses
21093489 2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model
20727913 2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus
31073993 2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives
32285908 2020. Chloroquine and bafilomycin A mimic lysosomal storage disorders and impair mTORC1 signalling
32243785 2020. Embracing the Landscape of Therapeutics
30993690 2019. Emerging viruses and current strategies for vaccine intervention
32099652 2020. Frontiers in antiviral therapy and immunotherapy
32259744 2020. DNA vaccines: prime time is now
32387642 2020. Innovations in structure-based antigen design and immune monitoring for next generation vaccines
C7163352 ä. Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential
32382358 ä. COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher?s Stone?
32377559 ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
32387262 ä. Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
C7118608 ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System
C7117595 ä. Drug repurposing strategies for COVID-19
16022774 2005. (+)SARS Vaccine Development
28861908 2017. (+)Issues in vaccinology: Present challenges and future directions
16433589 2006. (+)Antiviral applications of RNAi for coronavirus
32318055 2020. Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools
32362826 2020. Editorial: New Advances in RNA Targeting
32201439 2020. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach
32081774 2020. Discovery and development of safe-in-man broad-spectrum antiviral agents
32386655 2020. Influence of immune aging on vaccine responses
32281318 2020. Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying
32105468 2020. Structure-Based Stabilization of Non-native Protein?Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design
16697221 2006. (+)Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus
32388486 2020. Light as a potential treatment for pandemic coronavirus infections: A perspective
C7202831 ä. Testing COVID-19 therapies to prevent progression of mild disease
C7202844 ä. Vaccine development during global epidemics: the Zika experience
32380023 ä. Immunomodulation in COVID-19
32444269 ä. Immunotherapies for COVID-19: lessons learned from sepsis
32409074 2020. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents
C7190528 ä. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
32373787 2020. A new paradigm for drug development
32359447 2020. The resurgence of convalescent plasma therapy
32325038 ä. (+)Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
32325036 ä. Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?
| 29329956 2018. Herd immunity: hyperimmune globulins for the 21st century |
31351923 2019. (+)First clinical trial of a MERS coronavirus DNA vaccine
28664850 2017. (+)Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome
29852530 2020. The expanding role of mass spectrometry in the field of vaccine development
31432544 2020. Repurposing approved drugs on the pathway to novel therapies
31692019 2020. (+)Gold nanoparticle?adjuvanted S protein induces a strong antigen?specific IgG response against severe acute respiratory syndrome?related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs
32197324 2020. A Review on Applications of Computational Methods in Drug Screening and Design
20956884 2010. (+)Small Interfering RNA Effectively Inhibits the Expression of SARS Coronavirus Membrane Gene at Two Novel Targeting Sites
32317764 ä. Developing therapeutic monoclonal antibodies at pandemic pace
32387334 ä. The Forrest Gump approach to preventing severe COVID-19 ? reverse the predisposing pro-inflammatory state with exercise
32376359 2020. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
32382315 2020. Can graphene take part in the fight against COVID-19?
32313660 2020. A short review on antibody therapy for COVID-19
32377399 2020. COVID-19 vaccines: breaking record times to first-in-human trials
32380052 2020. Granulocyte-targeted therapies for airway diseases
32389754 ä. (low dose radiat)RILI model and the Covid-19 pneumonia: The radiation oncologist point of view?
32387544 ä. Response to: Low dose radiation therapy for COVID-19 pneumonia a double-edged sword?
32448638 2020. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike
32417123 ä. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike
32418793 2020. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors? CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
32381478 2020. Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro
32061923 2020. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
32208449 2020. BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses
32355446 2020. Medicaments rhumatologiques pour le traitement de l?infection par le COVID-19?
16043204 2005. (+)Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
31930543 2020. Inactivation of three emerging viruses ? severe acute respiratory syndrome coronavirus, Crimean?Congo haemorrhagic fever virus and Nipah virus ? in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light
